{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:48:57Z","timestamp":1792460937769,"version":"4.5.0"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T00:00:00Z","timestamp":1346889600000},"content-version":"vor","delay-in-days":218,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p>\n                    A 56\u2010week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled\u2010release combination of phentermine and topiramate (PHEN\/TPM CR) for weight loss (WL) and metabolic improvements. Men and women with class II and III obesity (BMI \u2265 35 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) were randomized to placebo, PHEN\/TPM CR 3.75\/23 mg, or PHEN\/TPM CR 15\/92 mg, added to a reduced\u2010energy diet. Primary end points were percent WL and proportions of patients achieving 5% WL. Secondary end points included waist circumference (WC), systolic and diastolic blood pressure (BP), fasting glucose, and lipid measures. In the primary analysis (randomized patients with at least one postbaseline weight measurement who took at least one dose of assigned drug or placebo), patients in the placebo, 3.75\/23, and 15\/92 groups lost 1.6%, 5.1%, and 10.9% of baseline body weight (BW), respectively, at 56 weeks (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.0001). In categorical analysis, 17.3% of placebo patients, 44.9% of 3.75\/23 patients, and 66.7% of 15\/92 patients, lost at least 5% of baseline BW at 56 weeks (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.0001). The 15\/92 group had significantly greater changes relative to placebo for WC, systolic and diastolic BP, fasting glucose, triglycerides, total cholesterol, low\u2010density lipoprotein (LDL), and high\u2010density lipoprotein (HDL). The most common adverse events were paresthesia, dry mouth, constipation, dysgeusia, and insomnia. Dropout rate from the study was 47.1% for placebo patients, 39.0% for 3.75\/23 patients, and 33.6% of 15\/92 patients. PHEN\/TPM CR demonstrated dose\u2010dependent effects on weight and metabolic variables in the direction expected to be beneficial with no evidence of serious adverse events induced by treatment.\n                  <\/jats:p>","DOI":"10.1038\/oby.2011.330","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T09:43:20Z","timestamp":1320313400000},"page":"330-342","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":597,"title":["Controlled\u2010Release Phentermine\/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)"],"prefix":"10.1002","volume":"20","author":[{"given":"David B.","family":"Allison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore M.","family":"Gadde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Timothy","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Schwiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Najarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Troupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,6]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.231"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80057-9"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jada.2007.07.017"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31817fde95"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802783"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.102"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.03.053"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-9007(00)00452-4"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801873"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2000.84"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.78"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2004.206"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0220-1"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803382"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(95)00113-R"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/1028415031000120552"},{"key":"e_1_2_8_18_2","unstructured":"Topamax [product information].Ortho\u2010McNeil\u2010Janssen Pharmaceuticals Inc.: Titusville NJ 2009."},{"key":"e_1_2_8_19_2","first-page":"146","article-title":"Weight loss at 6 months with VI\u20100521 (PHEN\/TPM combination) treatment","volume":"3","author":"Ryan D","year":"2010","journal-title":"Obes Facts"},{"key":"e_1_2_8_20_2","volume-title":"The LEARN Program for Weight Management","author":"Brownell KD","year":"2004"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.7.826"},{"key":"e_1_2_8_22_2","first-page":"A17","article-title":"A 24\u2010week randomized controlled trial of VI\u20100521, a combination weight loss therapy, in obese adults [abstract]","volume":"14","author":"Gadde KM","year":"2006","journal-title":"Obesity"},{"key":"e_1_2_8_23_2","volume-title":"Guidance for Industry: Developing Products for Weight Management","author":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research","year":"2007"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(00)00046-5"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006624"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007312"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543400902964118"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.624"},{"key":"e_1_2_8_30_2","unstructured":"Adipex\u2010P [product information].Teva Pharmaceuticals USA: Sellersville PA 2005."},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"e_1_2_8_32_2","volume-title":"The Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report","author":"National Heart, Lung, and Blood Institute","year":"1998"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.2014"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909809"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789X.2003.00109.x"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789x.2000.00004.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39385.413113.25"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2002.00236.x"},{"key":"e_1_2_8_41_2","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein DJ","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(90)90299-R"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.14.1724"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-9-200605020-00005"},{"key":"e_1_2_8_45_2","volume-title":"Multiple Imputation for Non\u2010Response in Surveys. Wiley Series in Probability and Mathematical Statistics","author":"Rubin DB","year":"1987"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781439821862"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Foby.2011.330","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Foby.2011.330","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/oby.2011.330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T17:22:53Z","timestamp":1697563373000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/oby.2011.330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1038\/oby.2011.330"],"URL":"https:\/\/doi.org\/10.1038\/oby.2011.330","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"2012-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}